China Girl, 6, Dies After First Brain Base-Editing Trial as $860,000 Family-Funded Study Faces Scrutiny
Updated
Updated · The Hindu · Jul 26
China Girl, 6, Dies After First Brain Base-Editing Trial as $860,000 Family-Funded Study Faces Scrutiny
3 articles · Updated · The Hindu · Jul 26
Summary
A six-year-old girl died a week after a March 24, 2025 injection in Shanghai of what researchers called the first base-editing therapy delivered to the brain.
Hospital reviewers tied the death to the treatment, saying high-dose AAV delivery triggered thrombotic microangiopathy; the child developed fever and kidney damage within days.
Science and Retraction Watch said monkey toxicology studies had already shown liver injury in all treated animals and kidney damage in one, raising questions about whether safety evidence justified human use.
The investigator-initiated trial at Xinhua Hospital did not need prior review by China’s national drug regulator; local authorities later fined the hospital over oversight and registration failures but did not sanction lead researcher Zilong Qiu.
Nature said it was not told about the death or regulatory issues before publishing related preclinical work, sharpening broader debate over oversight of first-in-human gene-editing trials.
Why did a prestigious journal publish a gene-editing success story while hiding the tragic death of the child who funded it?
How did an unapproved, highly toxic gene therapy bypass national regulators to be injected into a child's brain for $860,000?
Mei’s Case: How a $860,000 Gene Therapy Trial Ended in Tragedy and Sparked a Global Scandal Over Scientific Integrity
Overview
In March 2025, Mei’s parents raised $860,000 to fund a custom gene-editing treatment for their daughter’s rare syndrome. Doctors at Shanghai Xinhua Hospital, bypassing national regulators, injected trillions of engineered AAV vectors into Mei’s spinal canal. Within days, she developed severe complications and died from a fatal immune reaction called thrombotic microangiopathy. The research team later published a paper omitting Mei’s death and key safety data. The cover-up was exposed in July 2026, sparking outrage and calls for investigation. This tragedy highlighted how high viral loads in gene therapy can trigger deadly immune responses, and exposed dangerous gaps in clinical oversight.